Cargando…

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease

INTRODUCTION: We examine the role of brain apolipoprotein B (apoB) as a putative marker of early tau pathology and cognitive decline. METHODS: Cerebrospinal fluid (CSF) samples from cognitively normal and Alzheimer's disease (AD) participants were collected to measure protein levels of apoB and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Picard, Cynthia, Nilsson, Nathalie, Labonté, Anne, Auld, Daniel, Rosa‐Neto, Pedro, Ashton, Nicholas J., Zetterberg, Henrik, Blennow, Kaj, Breitner, John C.B., Villeneuve, Sylvia, Poirier, Judes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293308/ https://www.ncbi.nlm.nih.gov/pubmed/34590423 http://dx.doi.org/10.1002/alz.12442

Ejemplares similares

Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum
por: Nilsson, Nathalie I. V., et al.
Publicado: (2021)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study
por: Picard, Cynthia, et al.
Publicado: (2019)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease
por: Vogel, Jacob W, et al.
Publicado: (2018)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis
por: Meyer, Pierre-François, et al.
Publicado: (2018)

Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease
por: Leduc, Valérie, et al.
Publicado: (2011)

No apparent effect of naproxen on CSF markers of innate immune activation
por: Meyer, Pierre‐François, et al.
Publicado: (2019)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

Tau as a fluid biomarker of concussion and neurodegeneration
por: Hossain, Iftakher, et al.
Publicado: (2022)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
por: St-Onge, Frédéric, et al.
Publicado: (2023)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
por: Zettergren, Anna, et al.
Publicado: (2021)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee
por: Strandhagen, Elisabeth, et al.
Publicado: (2004)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hsv66ahs24a1hpdi9gu5sk0jj8